The first MASH drug could open the door for others — including GLP-1s

With only one approved drug on the market, companies like Inventiva Pharma are advancing MASH drugs and seeking a competitive edge.

By Amy Baxter • Nov. 18, 2024

Where are they now? 4 biotechs that soared then crashed during the pandemic

How Novavax and others have restructured and trudged forward after their COVID-era high.

By Meagan Parrish • Nov. 15, 2024

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Left to clean up after ‘pharma bro’ Shkreli’s arrest, former Turing CEO Ron Tilles reckons with the past

While Martin Shkreli smirked his way through a public securities fraud investigation, Ron Tilles became interim CEO of Turing Pharmaceuticals, ready or not. Here’s his story.

By Michael Gibney • Nov. 14, 2024

From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies

As the industry’s marketing dollars shift, companies are targeting potential patients in unique ways.

By Amy Baxter • Nov. 13, 2024

Pharma’s grip on cancer R&D is having unintended consequences

A pair of studies paint a complicated picture of funding and missed research opportunities.

By Alexandra Pecci • Nov. 12, 2024

Pfizer and Lilly’s telehealth prescribing platforms draw Senate scrutiny for ‘potential fraud’

As Big Pharma embraces telehealth to sell medicines directly to patients, lawmakers wonder whether the programs skirt anti-kickback rules.

By Kelly Bilodeau • Nov. 12, 2024

Spravato is just the beginning in a new wave of depression meds

Psychiatry is getting more targeted as drugmakers develop a new range of treatments for depression.

By Meagan Parrish • Nov. 11, 2024

What RFK Jr.’s influence could mean for pharma

Past comments hint at the changes Robert F. Kennedy Jr. could make across the various sectors of healthcare. 

By Amy Baxter • Nov. 8, 2024

With Trump victorious, biotech industry’s focus turns to his plans for FDA, FTC

Speculation around pharma dealmaking and the next FDA commissioner has begun.

By Ned Pagliarulo , Ben Fidler • Nov. 8, 2024

Among 2024’s modest M&A action, cancer, immunology and neuroscience deals trickle in

Dealmaking this year has been largely muted, but M&A trends are pointing to the areas where pharma is placing the most emphasis.

By Michael Gibney • Nov. 7, 2024

An RNAi renaissance is creating a new generation of startups

Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is building on that foundation by taking the drugmaking technology in new directions.

By Gwendolyn Wu • Nov. 7, 2024

A diabetes drug, twice rejected, stumbles again — but its developer persists

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 diabetes therapy.   

By Amy Baxter • Nov. 6, 2024

CEO with type 1 diabetes works to deliver ‘world’s first’ functional cure

Sernova’s technology helped type 1 diabetes patients achieve insulin independence in early- and mid-stage trials.

By Alexandra Pecci • Nov. 5, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus

The pernicious and widespread virus has been linked to a range of diseases including MS and long COVID.

By Kelly Bilodeau • Nov. 4, 2024

Pfizer’s quest for market share in the ‘high stakes battleground’ of oral GLP-1s

Pfizer’s second-to-market goals for its oral GLP-1 drugs underscore big opportunities in the space.

By Amy Baxter • Nov. 4, 2024

A sickle cell cure exists. But patients need more than just gene therapy.

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.

By Alexandra Pecci • Nov. 1, 2024

2024 PharmaVoice 100s: Cancer Care Visionaries

Leaders who envision a world without cancer through oncology innovation.

By Michael Gibney • Nov. 1, 2024

Big Pharma earnings hang hope on the next generation of blockbusters

Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.

By Michael Gibney • Oct. 31, 2024

2024 PharmaVoice 100s: Clinical Trial Pros

Experts raising the bar in clinical trial design and collaboration.

By Amy Baxter • Oct. 31, 2024

Backlash builds against Novo’s Catalent takeover

Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.

By Amy Baxter • Oct. 30, 2024

2024 PharmaVoice 100s: Rare Disease Warriors

Pharma pros driving drug development and access for patients with high unmet needs. 

By Meagan Parrish • Oct. 29, 2024

How AZ’s respiratory wins are ramping up for a bigger prize in COPD

As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.

By Michael Gibney • Oct. 29, 2024

Where Big Pharma’s campaign cash is flowing in this election

Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.

By Amy Baxter • Oct. 28, 2024

On the front lines of the superbug war, new treatments can’t arrive soon enough

As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.

By Kelly Bilodeau • Oct. 28, 2024

J&J’s comeback kid Spravato heads for blockbuster status

After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.

By Meagan Parrish • Oct. 25, 2024